Literature DB >> 27288072

Kynurenines and Glutamate: Multiple Links and Therapeutic Implications.

R Schwarcz1.   

Abstract

Glutamate is firmly established as the major excitatory neurotransmitter in the mammalian brain and is actively involved in most aspects of neurophysiology. Moreover, glutamatergic impairments are associated with a wide variety of dysfunctional states, and both hypo- and hyperfunction of glutamate have been plausibly linked to the pathophysiology of neurological and psychiatric diseases. Metabolites of the kynurenine pathway (KP), the major catabolic route of the essential amino acid tryptophan, influence glutamatergic activity in several distinct ways. This includes direct effects of these "kynurenines" on ionotropic and metabotropic glutamate receptors or vesicular glutamate transport, and indirect effects, which are initiated by actions at various other recognition sites. In addition, some KP metabolites affect glutamatergic functions by generating or scavenging highly reactive free radicals. This review summarizes these phenomena and discusses implications for brain physiology and pathology.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Glial cells; Kynurenic acid; Neuroprotection; Quinolinic acid

Mesh:

Substances:

Year:  2016        PMID: 27288072      PMCID: PMC5803753          DOI: 10.1016/bs.apha.2016.01.005

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  152 in total

1.  Anticonvulsant effects of the 3-hydroxyanthranilic acid dioxygenase inhibitor NCR-631.

Authors:  J Luthman
Journal:  Amino Acids       Date:  2000       Impact factor: 3.520

2.  Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor.

Authors:  Roberto Pellicciari; Rosa C Rizzo; Gabriele Costantino; Maura Marinozzi; Laura Amori; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  ChemMedChem       Date:  2006-05       Impact factor: 3.466

Review 3.  Excitatory amino acid transmitters.

Authors:  J C Watkins; R H Evans
Journal:  Annu Rev Pharmacol Toxicol       Date:  1981       Impact factor: 13.820

4.  On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress.

Authors:  R Lugo-Huitrón; T Blanco-Ayala; P Ugalde-Muñiz; P Carrillo-Mora; J Pedraza-Chaverrí; D Silva-Adaya; P D Maldonado; I Torres; E Pinzón; E Ortiz-Islas; T López; E García; B Pineda; M Torres-Ramos; A Santamaría; V Pérez-De La Cruz
Journal:  Neurotoxicol Teratol       Date:  2011-07-13       Impact factor: 3.763

5.  Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.

Authors:  J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

6.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

7.  Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus.

Authors:  F Nicoletti; J L Meek; M J Iadarola; D M Chuang; B L Roth; E Costa
Journal:  J Neurochem       Date:  1986-01       Impact factor: 5.372

8.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

9.  Direct measurement of glutamate release in the brain using a dual enzyme-based electrochemical sensor.

Authors:  Y Hu; K M Mitchell; F N Albahadily; E K Michaelis; G S Wilson
Journal:  Brain Res       Date:  1994-10-03       Impact factor: 3.252

10.  Quinolinic acid induces disrupts cytoskeletal homeostasis in striatal neurons. Protective role of astrocyte-neuron interaction.

Authors:  Paula Pierozan; Fernanda Ferreira; Bárbara Ortiz de Lima; Regina Pessoa-Pureur
Journal:  J Neurosci Res       Date:  2014-10-13       Impact factor: 4.164

View more
  18 in total

1.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

Review 2.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 3.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

4.  Influence of periodontal inflammation on tryptophan-kynurenine metabolism: a cross-sectional study.

Authors:  Şivge Kurgan; Canan Önder; Nur Balcı; Nihan Akdoğan; S Merve Altıngöz; Muhittin A Serdar; Meral Günhan
Journal:  Clin Oral Investig       Date:  2022-05-19       Impact factor: 3.606

5.  Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; Francesca M Notarangelo; S Andrea Wijtenburg; Marian A R Thomas; Ana Pocivavsek; Aaron Jones; Krista Wisner; Peter Kochunov; Robert Schwarcz; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2018-04-18       Impact factor: 7.853

6.  Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.

Authors:  Jie Wen; Prasanth S Ariyannur; Rachel Ribeiro; Mikiei Tanaka; John R Moffett; Batool F Kirmani; Aryan M A Namboodiri; Yumin Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

Review 7.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

8.  Glia- and tissue-specific changes in the Kynurenine Pathway after treatment of mice with lipopolysaccharide and dexamethasone.

Authors:  Carlos R Dostal; Nicolaus S Gamsby; Marcus A Lawson; Robert H McCusker
Journal:  Brain Behav Immun       Date:  2017-12-11       Impact factor: 7.217

9.  Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression.

Authors:  Ebrahim Haroon; James R Welle; Bobbi J Woolwine; David R Goldsmith; Wendy Baer; Trusharth Patel; Jennifer C Felger; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2020-01-15       Impact factor: 7.853

10.  N-Acetylcysteine Inhibits Kynurenine Aminotransferase II.

Authors:  T Blanco-Ayala; K V Sathyasaikumar; J D Uys; V Pérez-de-la-Cruz; L S Pidugu; R Schwarcz
Journal:  Neuroscience       Date:  2020-08-05       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.